← Leaderboards
Matthew Ryan Gardner
Emory University
$7,631,700
Attributed
$7,631,700
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.7M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,631,700 · 5
By mechanism
R01$6,852,499 · 2
R00$498,000 · 1
K99$165,443 · 1
F32$115,758 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Francois J Villinger$61,853,654
- Guido Silvestri$61,186,493
- Siddappa N Byrareddy$14,019,085
- Christian P Larsen$35,318,088
- Mandy L. Ford$29,844,446
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesAntiretroviral TherapyDoseAdeno-Associated Viral VectorTransgene ExpressionMacacaHiv-1Macaca MulattaInfectionDependovirusSimian Human Immunodeficiency VirusNeutralizing AntibodyMuscleIntramuscularInfusion ProceduresAntibody ResponseMediatingPharmaceutical PreparationsClinical TrialsHumanized MouseAnti-Retroviral AgentsHiv Entry InhibitorsGene TherapyGene Transduction Agent
Grant awards (15)
Optimizing AAV delivery of bNAbs for HIV prevention$881,378
R01 · FY2025 · AI · contact PI
AAV-delivered HIV inhibitors for SHIV therapy$801,157
R01 · FY2025 · DA · contact PI
Optimizing AAV delivery of bNAbs for HIV prevention$908,948
R01 · FY2024 · AI · contact PI
AAV-delivered HIV inhibitors for SHIV therapy$808,489
R01 · FY2024 · DA · contact PI
Optimizing AAV delivery of bNAbs for HIV prevention$909,998
R01 · FY2023 · AI · contact PI
AAV-delivered HIV inhibitors for SHIV therapy$809,507
R01 · FY2023 · DA · contact PI
Optimizing AAV delivery of bNAbs for HIV prevention$906,720
R01 · FY2022 · AI · contact PI
AAV-delivered HIV inhibitors for SHIV therapy$826,302
R01 · FY2022 · DA · contact PI
AAV-Delivered Broadly Neutralizing Antibodies for HIV Suppression$249,000
R00 · FY2021 · AI · contact PI
AAV-Delivered Broadly Neutralizing Antibodies for HIV Suppression$249,000
R00 · FY2020 · AI · contact PI
AAV-delivered broadly neutralizing antibodies for HIV suppression$35,573
K99 · FY2020 · AI · contact PI
AAV-delivered broadly neutralizing antibodies for HIV suppression$129,870
K99 · FY2019 · AI · contact PI
An AAV Approach to Treating HIV$59,166
F32 · FY2017 · AI · contact PI
An AAV Approach to Treating HIV$474
F32 · FY2017 · AI · contact PI
An AAV Approach to Treating HIV$56,118
F32 · FY2016 · AI · contact PI